Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | TNIK | Q9UKE5 | 5/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13312332 | 0.83 | APP (0.71) | APPALDH1A1TNIKRAB9A | |
| SCHEMBL13312326 | 0.83 | APP (1.00) | APPCDK2CHRNA3TNIKRAB9A | |
| SCHEMBL13312204 | 0.83 | APP (0.72) | APPMEN1ALDH1A1KMT2ATNIK | |
| SCHEMBL13312209 | 0.83 | APP (0.71) | APPALDH1A1KMT2ATNIKRAB9A | |
| SCHEMBL13312208 | 0.82 | APP (0.70) | APPMEN1ALDH1A1KMT2ATNIK | |
| SCHEMBL13312218 | 0.79 | APP (0.65) | APPCHRNA3TNIKRAB9A | |
| SCHEMBL13312323 | 0.79 | APP (1.00) | APPMEN1ALDH1A1KMT2ACDK1 | |
| SCHEMBL2321807 | 0.77 | CDK1 (0.52) | APPMEN1USP2ALDH1A1KMT2A | |
| SCHEMBL2321798 | 0.77 | CDK1 (0.52) | APPMEN1USP2ALDH1A1KMT2A | |
| SCHEMBL13312311 | 0.76 | APP (0.64) | APPALDH1A1KMT2ATNIKRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144793-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2010-06-10 | — | — | US | disclosed |
| US-20100144793-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144793-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | APP, BACE1, APBA1 | APP 1/4885MEN1 3842/4885USP2 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.